Off-Label Questions Linger: How Much Data Needed To Be 'Truthful'?
Executive Summary
FDA settlement with Amarin on Vascepa has done little to clarify what constitutes 'non-misleading' communications about an unapproved use.
You may also be interested in...
FDA Sets New Goal For Biosimilar, Drug Promotion Guidances
Agency plans to issue 102 new and revised draft guidances this year, including those on use of multiple endpoints in clinical trials, 180-day exclusivity, and ANDA refuse-to-receive standards.
FDA Guidance On Health Care Economic Data Is Coming In 2015
Agency originally said it would issue a draft guidance on industry’s interactions with formulary committees in 2014, but CDER Director Woodcock says “extremely contentious” issues have slowed progress.
FDA Promises More Off-label Guidances As Part Of First Amendment Harmonization
Agency grants two citizen petitions from a coalition of pharma companies requesting greater clarity from FDA, but whether the forthcoming guidances will satisfy industry remains an open question.